Complete Carney triad with succinate dehydrogenase subunit B-deficient gastric gastrointestinal stromal tumour in a patient treated with imatinib: A case report

BACKGROUNDCarney triad is a rare, non-hereditary multiple-tumour syndrome characterised by the synchronous or metachronous development of gastrointestinal stromal tumour (GIST), pulmonary chondroma, and paraganglioma/pheochromocytoma in a single patient.We report a case of complete Carney triad that presented with GIST and evolved over 21 years. CASE SUMMARYA 46-year-old woman presented with a gastric mass detected on computed tomography more than half a month earlier.She had undergone subtotal gastrectomy for gastric GIST in 2004, was subsequently diagnosed with pulmonary chondroma, and underwent re-resection of recurrent GIST in 2021, followed by 1 year of adjuvant imatinib that she discontinued on her own.In 2025, retroperitoneal and hepatic lesions emerged and were pathologically diagnosed as paraganglioma.Imatinib was reinitiated, and clinical improvement was reported; however, no objective radiological response assessment was performed, and imaging on November 19, 2025 showed disease progression.Therefore, the clinical improvement could not be attributed specifically to the succinate dehydrogenase (SDH)-deficient GIST, and imatinib efficacy in the GIST was not demonstrated.Immunohistochemistry revealed complete loss of SDH subunit B (SDHB) expression in all three tumour types.In the GIST, SDHB loss was confirmed in three independent paraffin blocks, supporting an SDH-deficient phenotype and reducing the likelihood of a false-negative immunohistochemical result. CONCLUSIONClinical improvement temporally associated with imatinib reinitiation in this patient with Carney triad and SDH-deficient GIST should be interpreted with caution.Without 4 / 25 objective response assessment or comprehensive molecular testing, and given the subsequent radiological progression, imatinib efficacy in the SDH-deficient GIST could not be established.

Authors

Institutions

Publication Details

Journal
World Journal of Gastroenterology
Published
2026-11-16
DOI
https://doi.org/10.3748/wjg.125257
Primary Topic
Gastrointestinal Tumor Research and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Complete Carney triad with succinate dehydrogenase subunit B-deficient gastric gastrointestinal stromal tumour in a patient treated with imatinib: A case report

Jie Zou, Si-Rui Wang, Jun Yang, Yi-Ping Wang et al.
1 links
World Journal of Gastroenterology
Gastrointestinal Tumor Research and Treatment
article

Complete Carney triad with succinate dehydrogenase subunit B-deficient gastric gastrointestinal stromal tumour in a patient treated with imatinib: A case report

Jie Zou, Si-Rui Wang, Jun Yang, Yi-Ping Wang, Hong-Yan Hu, Hao-Dan Huang, Hao-Tao Huang, Ming Tian
article en

Abstract

BACKGROUNDCarney triad is a rare, non-hereditary multiple-tumour syndrome characterised by the synchronous or metachronous development of gastrointestinal stromal tumour (GIST), pulmonary chondroma, and paraganglioma/pheochromocytoma in a single patient.We report a case of complete Carney triad that presented with GIST and evolved over 21 years. CASE SUMMARYA 46-year-old woman presented with a gastric mass detected on computed tomography more than half a month earlier.She had undergone subtotal gastrectomy for gastric GIST in 2004, was subsequently diagnosed with pulmonary chondroma, and underwent re-resection of recurrent GIST in 2021, followed by 1 year of adjuvant imatinib that she discontinued on her own.In 2025, retroperitoneal and hepatic lesions emerged and were pathologically diagnosed as paraganglioma.Imatinib was reinitiated, and clinical improvement was reported; however, no objective radiological response assessment was performed, and imaging on November 19, 2025 showed disease progression.Therefore, the clinical improvement could not be attributed specifically to the succinate dehydrogenase (SDH)-deficient GIST, and imatinib efficacy in the GIST was not demonstrated.Immunohistochemistry revealed complete loss of SDH subunit B (SDHB) expression in all three tumour types.In the GIST, SDHB loss was confirmed in three independent paraffin blocks, supporting an SDH-deficient phenotype and reducing the likelihood of a false-negative immunohistochemical result. CONCLUSIONClinical improvement temporally associated with imatinib reinitiation in this patient with Carney triad and SDH-deficient GIST should be interpreted with caution.Without 4 / 25 objective response assessment or comprehensive molecular testing, and given the subsequent radiological progression, imatinib efficacy in the SDH-deficient GIST could not be established.

World Journal of Gastroenterology
Kunming Medical University (CN), Peking University Cancer Hospital (CN)
National Natural Science Foundation of China, Applied Basic Research Foundation of Yunnan Province
Good health and well-being
Gastrointestinal Tumor Research and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon